Literature DB >> 31571234

BCL6 BTB-specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta).

Yanhui Cai1, Meagan A Watkins2, Fengtian Xue3, Yong Ai3, Huiming Cheng3, Cecily C Midkiff2, Xiaolei Wang2, Xavier Alvarez2, Adi Narayana Reddy Poli4, Joseph M Salvino4, Ronald S Veazey2, Luis J Montaner1.   

Abstract

BACKGROUND: The BTB domain of B-cell lymphoma 6 (BCL6) protein was identified as a therapeutic target for B-cell lymphoma. This study compared the pharmacokinetics (PK) of the BCL6 BTB inhibitor (FX1) between mice and macaques, as well as evaluating its lymphoid suppressive effect in uninfected macaques with lymphoid hyperplasia.
MATERIALS AND METHODS: Eight uninfected adult Indian rhesus macaques (Macaca mulatta) were used in the study, four animals carrying lymphoid tissue hyperplasia. Plasma FX1 levels were measured by HPLC-MS/MS. Lymph node biopsies were used for H&E and immunohistochemistry staining, as well as mononuclear cell isolation for flow cytometry analysis.
RESULTS: Inhibition of the BCL6 BTB domain with FX1 led to a reduction in the frequency of GC, Tfh CD4+ , and Tfh precursor cells, as well as resolving lymphoid hyperplasia, in rhesus macaques.
CONCLUSIONS: B-cell lymphoma 6 inhibition may represent a novel strategy to reduce hyperplastic lymphoid B-cell follicles and decrease Tfh cells.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell lymphoma 6; T follicular helper; germinal center reaction; lymphoid hyperplasia

Year:  2019        PMID: 31571234      PMCID: PMC7236024          DOI: 10.1111/jmp.12438

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  25 in total

Review 1.  Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications.

Authors:  Chiyoko Ueda; Takashi Akasaka; Hitoshi Ohno
Journal:  Leuk Lymphoma       Date:  2002-07

2.  Germinal Center Lymphocyte Ratios and Successful HIV Vaccines.

Authors:  Paula Gonzalez-Figueroa; Jonathan A Roco; Carola G Vinuesa
Journal:  Trends Mol Med       Date:  2017-01-12       Impact factor: 11.951

Review 3.  To scale or not to scale: the principles of dose extrapolation.

Authors:  Vijay Sharma; John H McNeill
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

4.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Authors:  Courtney V Fletcher; Kathryn Staskus; Stephen W Wietgrefe; Meghan Rothenberger; Cavan Reilly; Jeffrey G Chipman; Greg J Beilman; Alexander Khoruts; Ann Thorkelson; Thomas E Schmidt; Jodi Anderson; Katherine Perkey; Mario Stevenson; Alan S Perelson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

5.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.

Authors:  Mariano G Cardenas; Wenbo Yu; Wendy Beguelin; Matthew R Teater; Huimin Geng; Rebecca L Goldstein; Erin Oswald; Katerina Hatzi; Shao-Ning Yang; Joanna Cohen; Rita Shaknovich; Kenno Vanommeslaeghe; Huimin Cheng; Dongdong Liang; Hyo Je Cho; Joshua Abbott; Wayne Tam; Wei Du; John P Leonard; Olivier Elemento; Leandro Cerchietti; Tomasz Cierpicki; Fengtian Xue; Alexander D MacKerell; Ari M Melnick
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

6.  BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.

Authors:  Yanhui Cai; Mohamed Abdel-Mohsen; Costin Tomescu; Fengtian Xue; Guoxin Wu; Bonnie J Howell; Yong Ai; Jie Sun; Livio Azzoni; Carole Le Coz; Neil Romberg; Luis J Montaner
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

7.  Bcl6 mediates the development of T follicular helper cells.

Authors:  Roza I Nurieva; Yeonseok Chung; Gustavo J Martinez; Xuexian O Yang; Shinya Tanaka; Tatyana D Matskevitch; Yi-Hong Wang; Chen Dong
Journal:  Science       Date:  2009-07-23       Impact factor: 47.728

8.  The level of monocyte turnover predicts disease progression in the macaque model of AIDS.

Authors:  Atsuhiko Hasegawa; Huining Liu; Binhua Ling; Juan T Borda; Xavier Alvarez; Chie Sugimoto; Heather Vinet-Oliphant; Woong-Ki Kim; Kenneth C Williams; Ruy M Ribeiro; Andrew A Lackner; Ronald S Veazey; Marcelo J Kuroda
Journal:  Blood       Date:  2009-04-21       Impact factor: 22.113

9.  Persistent HIV-1 replication maintains the tissue reservoir during therapy.

Authors:  Ramon Lorenzo-Redondo; Helen R Fryer; Trevor Bedford; Eun-Young Kim; John Archer; Sergei L Kosakovsky Pond; Yoon-Seok Chung; Sudhir Penugonda; Jeffrey Chipman; Courtney V Fletcher; Timothy W Schacker; Michael H Malim; Andrew Rambaut; Ashley T Haase; Angela R McLean; Steven M Wolinsky
Journal:  Nature       Date:  2016-01-27       Impact factor: 49.962

Review 10.  Lymph Node Cellular and Viral Dynamics in Natural Hosts and Impact for HIV Cure Strategies.

Authors:  Nicolas Huot; Steven E Bosinger; Mirko Paiardini; R Keith Reeves; Michaela Müller-Trutwin
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

View more
  2 in total

1.  BCL6 BTB-specific inhibitor reversely represses T-cell activation, Tfh cells differentiation, and germinal center reaction in vivo.

Authors:  Yanhui Cai; Adi Narayana Reddy Poli; Surya Vadrevu; Kwasi Gyampoh; Colin Hart; Brian Ross; Matt Fair; Fengtian Xue; Joseph M Salvino; Luis J Montaner
Journal:  Eur J Immunol       Date:  2021-09-16       Impact factor: 5.532

2.  Targeting Bcl6 in the TREX1 D18N murine model ameliorates autoimmunity by modulating T-follicular helper cells and germinal center B cells.

Authors:  Rajkumar Venkatadri; Vikram Sabapathy; Murat Dogan; Saleh Mohammad; Scott E Harvey; Sean R Simpson; Jason M Grayson; Nan Yan; Fred W Perrino; Rahul Sharma
Journal:  Eur J Immunol       Date:  2022-02-15       Impact factor: 6.688

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.